Dantari’s polymer nanoparticle-drug conjugate clears PhI breast cancer hurdle, sparking PhII plans

Dantari’s drug conjugate asset has produced positive data as both a monotherapy and in combination with a PARP inhibitor in an early-stage breast cancer trial, paving the way for a Phase II test.

The biotech’s Phase I dose escalation trial studied DAN-222 as a single agent…
Click here to view original post

Advertisement — Advertise with Biotech Networks